Asia-inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enablerCTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82024-10-240OA
Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White PaperCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52024-07-070OAAI
Asia-Inclusive Global Development of Enpatoran: Results of an Ethno-Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical TrialCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52024-02-283OAAI
Model-based meta-analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosusCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32023-12-044OA
Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52023-10-233OAAI
Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ PerspectiveCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52023-03-166OAAI
Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug developmentCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32022-11-297OA
Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity modelsCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32022-08-058OAAI
Applying Modeling and Simulations for Rational Dose Selection of Novel Toll-Like Receptor 7/8 Inhibitor Enpatoran for Indications of High Medical NeedCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52022-05-2112OAAI
To blind or not to blind first in human and exploratory clinical trials: Acceleration of development vs. risk of biasCTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82021-11-281OA
Comparison of Various Phase I Combination Therapy Designs in Oncology for Evaluation of Early Tumor Shrinkage Using SimulationsCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32020-11-052OAAI
First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjectsBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32020-01-2825OAAI
Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic NephropathyKIDNEY INTERNATIONAL REPORTSIF5.72018-11-0143OAAI
Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation studyBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32018-05-2444OAAI
Prediction of Drug Clearance in Children: an Evaluation of the Predictive Performance of Several ModelsAAPS JOURNALIF3.72014-10-0241OAAI
Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosaBIOORGANIC & MEDICINAL CHEMISTRYIF32014-10-0126PREAI
Improvement of the Pharmacokinetics and In Vivo Antibacterial Efficacy of a Novel Type IIa Topoisomerase Inhibitor by Formulation in LiposomesANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52013-10-014OAAI
Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II with Reduced pKa: Antibacterial Agents with an Improved Safety ProfileJOURNAL OF MEDICINAL CHEMISTRYIF6.82012-07-2084PREAI
Prediction of Human Drug Clearance from Two Species: A Comparison of Several Allometric MethodsJOURNAL OF PHARMACEUTICAL SCIENCESIF3.82010-03-0116PREAI
Efficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosisKIDNEY INTERNATIONALIF12.62006-06-0133OAAI